Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
We are sub £5m mcap
With a mcap of £4.9 and Germany calling…
Due to receive the following in Q1/early Q2
€2.8 million first payment Leap
£250,000 loan repayment Leap
£150,000 CLN SWB (up on 16/1/23)
£600,000 2 year CLN Northern Leaf (up end Q1)
10% per annum interest with the above (£120,000)
https://cannatechtoday.com/adult-use-in-germany-will-revolutionize-cannabis-inventory-strategies/
We are sub £5m mcap
Due to receive the following in Q1/early Q2
€2.8 million first payment Leap
£250,000 loan repayment Leap
£150,000 CLN SWB (up on 16/1/23)
£600,000 2 year CLN Northern Leaf (up end Q1)
10% per annum interest with the above (£120,000)
Bar longlad all the folks that wanted to leave have all exited the building.
The only people willing to buy are LTH following Ed Mac’s obvious signal and are averaging down slowly and steadily trying to absorb the last of the distressed sales without putting any unwanted upward pressure on the SP.
Read
https://cannatechtoday.com/edge-of-your-seat-germanys-timetable-for-cannabis-legalization/
venescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
https://twitter.com/greenhamneggs/status/1614711914831003653?s=46&t=dNCUcBtp802kUwtXggE5vg